Use of D9-methadone for postoperative pain relief

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Patent US12590054B2 to the Board of Regents, The University of Texas System, covering the use of d9-methadone as an alternative formulation for methadone with improved pharmacokinetic properties for postoperative pain relief. The patent includes 15 claims and covers compositions and methods for managing pain following injury, disease, or surgery.

View original document View source feed page

What changed

USPTO issued Patent No. US12590054B2 to the Board of Regents, The University of Texas System, covering the therapeutic use of d9-methadone for pain management. The patent claims a compound with improved absorption-distribution-metabolism-excretion (ADME) profile, analgesic efficacy, and safety compared to conventional methadone. Inventors include Tatiana N. Nanovskaya, Jun-Ho La, Mahmoud S. Ahmed, and Jigong Wang.

Pharmaceutical companies and healthcare providers should review this patent for potential licensing implications when developing or using methadone-based pain treatments. Freedom-to-operate analyses should consider this IP if developing similar compounds. The patent term extends 20 years from the December 22, 2022 filing date.

Source document (simplified)

← USPTO Patent Grants

Use of D9-methadone for postoperative pain relief

Grant US12590054B2 Kind: B2 Mar 31, 2026

Assignee

Board of Regents, The University of Texas System

Inventors

Tatiana N. Nanovskaya, Jun-Ho La, Mahmoud S. Ahmed, Jigong Wang

Abstract

Certain embodiments are directed to the use of d9-methadone as an alternative formulation for methadone, the d9-methadone having an improved absorption-distribution-metabolism-excretion profile, analgetic efficacy, and safety for the management of pain following injury such as trauma, disease, and surgery.